Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience

Relapse of chronic lymphocytic leukemia (CLL) after allogeneic hematopoietic cell transplantation (HCT) remains a clinical challenge. We studied in a phase II trial whether the addition of peri-transplant rituximab would reduce the relapse risk compared to historical controls (n=157). Patients (n=55...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Bone Marrow Transplant
Päätekijät: Shadman, Mazyar, Maloney, David G., Storer, Barry, Sandmaier, Brenda M., Chauncey, Thomas R., Andersen, Niels Smedegaard, Niederwieser, Dietger, Shizuru, Judith, Bruno, Benedetto, Pulsipher, Michael A., Maziarz, Richard T., Agura, Edward D., Hari, Parameswaran, Langston, Amelia A., Maris, Michael B., McSweeney, Peter A, Storb, Rainer, Sorror, Mohamed L.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2019
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6940535/
https://ncbi.nlm.nih.gov/pubmed/31481800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41409-019-0660-8
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia